Precision Begins Patient Enrolment for FUNCTION-DMD Trial

Why It Matters

The trial marks the first clinical use of Precision’s ARCUS platform for DMD, potentially delivering a disease‑modifying therapy to a majority of affected boys and shaping the gene‑editing market.

Key Takeaways

• First site opened for Phase I/II FUNCTION‑DMD trial
• PBGENE‑DMD targets exon 45‑55 deletions covering 60% of DMD boys
• Therapy uses ARCUS gene‑editing via AAV vector
• Trial includes immune modulation and safety monitoring
• PBGENE‑DMD holds orphan‑drug and fast‑track designations

Pulse Analysis

Duchenne muscular dystrophy remains one of the most severe pediatric neuromuscular disorders, affecting roughly 1 in 3,500 male births. Traditional treatments address symptoms but do not correct the underlying genetic defect. Gene‑editing technologies, especially in‑vivo approaches, have emerged as a potential game‑changer, offering the promise of durable dystrophin restoration. Precision BioSciences’ ARCUS platform leverages a proprietary CRISPR‑derived nuclease delivered by a single adeno‑associated virus, aiming to excise exons 45‑55—a mutation hotspot that accounts for a large share of DMD cases.

The initiation of patient enrolment at Arkansas Children’s Hospital signals a pivotal step toward clinical validation. By focusing on ambulatory children aged two to seven, the FUNCTION‑DMD trial targets a window where muscle function can still be meaningfully improved. Safety and tolerability are front‑line endpoints, but the study also measures dystrophin protein expression and functional outcomes, providing early signals of therapeutic efficacy. Immune modulation protocols are built into the design to mitigate AAV‑related responses, reflecting lessons learned from earlier gene‑therapy trials.

Beyond the immediate trial, PBGENE‑DMD’s orphan‑drug and fast‑track statuses, plus eligibility for a pediatric rare‑disease priority‑review voucher, accelerate its regulatory pathway and commercial potential. Success could position Precision as a leader in the nascent market for gene‑edited therapies, prompting competitors to advance their own exon‑skipping or CRISPR strategies. Moreover, a positive readout would reinforce investor confidence in in‑vivo editing platforms, potentially unlocking further capital for pipeline expansion into other genetic diseases such as chronic hepatitis B, where Precision recently received trial approval for PBGENE‑HBV.